Gravas, Stavros
Manuel-Palacios, Juan
Chavan, Chandrashekhar http://orcid.org/0000-0002-9188-9575
Roehrborn, Claus G.
Oelke, Matthias
Averbeck, Marcio Augusto http://orcid.org/0000-0002-8127-7153
Biswas, Arunangshu
García, Llenalia María
Mohamed, Khadeeja
Cortes, Vanessa
Funding for this research was provided by:
GSK
Article History
Received: 4 August 2023
Revised: 14 September 2023
Accepted: 21 September 2023
First Online: 4 October 2023
Competing interests
: SG received research grants and/or honoraria from Astellas, GSK, Lilly, and Pierre Fabre Medicament. CGR received honoraria from and acted as a consultant for GSK. MO has been a speaker, consultant, and/or trial participant for Apogepha, Astellas, Duchesnay, Ferring, GSK, Lilly, Pierre Fabre, Pfizer, and SAJA Pharma, and received research grants from Astellas and Pfizer. MAA is an internal expert for GSK. JMP, VC, CC, AB, and KM are employees of and hold stocks/shares in GSK. LMG is an employee of Parexel; Parexel received funding from GSK to support the conduct of this study.
: No direct subject contact or primary collection of individual human subject data has occurred. Study results are in tabular form and presented as aggregate analyses that omit subject identification; therefore, informed consent, ethics committee, or institutional review board approval were not required.